Cordis announced the FDA has approved its self-expanding vascular stent designed for transradial peripheral procedures in the iliac and superficial femoral arteries. The self-expanding stent ...
A final option, less commonly used, is a technique called atherectomy. This treatment uses a device that cuts or grinds away the hardened deposition (atheroma) within the artery. Atherectomy is less ...
NATICK, Mass. and SAN FRANCISCO, Boston Scientific Corporation welcomed positive outcomes from the COBRA clinical trial, which evaluated post-dilation of nitinol stents using CryoPlasty® Therapy with ...
ATLANTA--(BUSINESS WIRE)-- According to THE SAGE GROUP, almost 70% of the procedures performed to treat Peripheral Artery Disease (PAD) were endovascular (angioplasty, atherectomy and primary stenting ...
NEW YORK, Jan. 12, 2021 /PRNewswire/ -- Growing prevalence of peripheral vascular disease across the globe is expected to increase demand for peripheral stent implants. Further, rising adoption of ...
SAN ANTONIO – Dr. Christopher Busken with Northeast Baptist Hospital has performed surgeries for about 15 years to help people who suffer from peripheral artery disease (PAD). PAD happens when ...
Peripheral artery disease (PAD) involves a debilitating narrowing of arteries in the legs, and the National Institutes of Health estimates that 1 in every 20 Americans over 50 is affected. Research ...
(MENAFN- iCrowdNewsWire) The global Peripheral Stent Implants Market is expected to stimulate at a good rate In Upcoming Years. Virtual consultations are amongst the ongoing trends. They mitigate the ...
ATLANTA, GA (March 14, 2006) -- Cardiologists are continually searching for the most effective and non-invasive methods of treatment for their patients. Two studies presented today at the American ...
TORONTO--(BUSINESS WIRE)--According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, Cook Medical’s Zilver PTX drug-eluting stent is likely to be ...
NATICK, Mass., Boston Scientific Corporation today announced that it has completed enrollment in the ORION clinical trial, which is designed to evaluate the Company's EPIC™ Self-Expanding Nitinol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results